CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

The Importance of Medical Writing in Emerging Healthcare Landscape

The Importance of Medical Writing in...

Life Science Sector All Set to Soar Via a Technology-driven Approach

Life Science Sector All Set to Soar...

A Convergence-deemed Capital To Accelerate the Marketing Insights of the Life Science Sector

A Convergence-deemed Capital To...

The Future of Life Sciences Regulation

The Future of Life Sciences Regulation

Prognosis for Life Science Regulation

Prognosis for Life Science Regulation

Major Compliance Challenges Facing The Life Science Industry In 2022

Major Compliance Challenges Facing...

How Pharmaceutical Automation is Revolutionizing Drug Development

How Pharmaceutical Automation is...

Major Challenges In The Evolving Era Of Life Sciences

Major Challenges In The Evolving Era...

The Importance of Medical Writing in Emerging Healthcare Landscape

The Importance of Medical Writing in...

Life Science Sector All Set to Soar Via a Technology-driven Approach

Life Science Sector All Set to Soar...

A Convergence-deemed Capital To Accelerate the Marketing Insights of the Life Science Sector

A Convergence-deemed Capital To...

The Future of Life Sciences Regulation

The Future of Life Sciences Regulation

Prognosis for Life Science Regulation

Prognosis for Life Science Regulation

Major Compliance Challenges Facing The Life Science Industry In 2022

Major Compliance Challenges Facing...

How Pharmaceutical Automation is Revolutionizing Drug Development

How Pharmaceutical Automation is...

Major Challenges In The Evolving Era Of Life Sciences

Major Challenges In The Evolving Era...

Major Risk Considerations for Life Sciences Industry

Life Sciences Review | Thursday, February 18, 2021
Tweet

Establishing and maintaining an in-house team, leading life sciences organizations periodically fill compliance gap assessments and enhance monitoring programs.


FREMONT, CA: The life sciences industry faces several existing and emerging challenges from a regulatory and compliance perspective, posing a constant threat to sustainability processes. Companies that can effectively handle these concerns can take a more proactive stance on risk, stick to evolving regulatory standards and ultimately create a competitive advantage. The following are key takeaways that life sciences organizations should consider to deploy controls that promote compliance and deter fraud and corruption.


Regulatory enforcement in the life sciences industry continues to increase, forcing firms to continually evaluate their risk and assess their present compliance programs' adequacy. Due to the present regulatory environment, life sciences firms must take steps to know new and emerging risks to rapidly respond and adapt. This latest scrutiny has resulted in a dramatic rise in defendants charged in health-care-related fraud cases. Given the increased regulatory enforcement activities, life sciences firms should be mindful of risks and create controls that limit malicious activities. 


Check Out: Top Pharma and Life Science Consulting Companies


Life sciences firms are particularly susceptible in a few specific areas.


The European Union’s General Data Protection Regulation (GDPR) needs all firms that hold, transmit or process EU data to comply with the law, regardless of whether firms or contracted third parties function in the EU. GDPR raises the bar for securing consumer information and needs specific tracking from collection to disposal. To address these and data security concerns, firms should periodically audit security and privacy strategies, amend controls and planning as required, align governance appropriately and have an incident response plan in place.


Due to the nature of their business, life sciences firms encounter more bribery and corruption than other industry segments. These firms often must interact with foreign and domestic governmental entities and officials, inherently generating higher public corruption risks. Also, many firms continue to assess their compliance and internal audit functions to decide whether their resources have adequate knowledge and experience. Regulatory authorities look favorably upon firms who have actively taken steps to follow guidance and deploy effective programs.


Weekly Brief

loading
Top 10 Life Sciences Compliance Solutions Companies - 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/major-risk-considerations-for-life-sciences-industry--nwid-262.html